Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Current Deferred Revenue for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 95.31% to $6.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 95.31% decrease, with the full-year FY2025 number at $6.7 million, down 95.31% from a year prior.
  • Current Deferred Revenue was $6.7 million for Q4 2025 at Beam Therapeutics, down from $110.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $338.2 million in Q4 2022 to a low of $6.7 million in Q4 2025.
  • A 5-year average of $126.4 million and a median of $115.0 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 1249900.0% in 2021, then crashed 95.31% in 2025.
  • Beam Therapeutics' Current Deferred Revenue stood at $300.0 million in 2021, then grew by 12.72% to $338.2 million in 2022, then tumbled by 47.19% to $178.6 million in 2023, then decreased by 20.45% to $142.1 million in 2024, then plummeted by 95.31% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Current Deferred Revenue are $6.7 million (Q4 2025), $110.3 million (Q3 2025), and $105.8 million (Q2 2025).